Is there a correlation of positive peritoneal washing cytology during interval debulking surgery on the survival outcomes of ovarian cancer patients? A systematic review and meta-analysis of the literature.


Journal

Journal of gynecology obstetrics and human reproduction
ISSN: 2468-7847
Titre abrégé: J Gynecol Obstet Hum Reprod
Pays: France
ID NLM: 101701588

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 19 08 2021
revised: 10 10 2021
accepted: 15 10 2021
pubmed: 23 10 2021
medline: 13 1 2022
entrez: 22 10 2021
Statut: ppublish

Résumé

The aim of the present study was to evaluate the prognostic impact of peritoneal washing cytology (PWC) on progression-free (PFS) and overall survival (OS) of patients undergoing interval debulking surgery (IDS) after neoadjuvant chemotherapy (NACT) for ovarian cancer (OC). We systematically searched Medline (1966-2020), Scopus (2004-2020), EMBASE (1980-2020), Cochrane Central Register of Controlled Trials CENTRAL (1999-2020), Clinicaltrials.gov (2008-2020) and Google Scholar (2004-2020). All the studies that investigated the correlation of peritoneal washing cytology with survival outcomes of patients undergoing interval debulking for ovarian cancer, were finally included in the present meta-analysis. A total of 7 retrospective studies were included, comprising 907 patients, of whom 535 had positive peritoneal washing cytology on interval debulking surgery. The methodological quality of the included studies was assessed as moderate, primarily due to the lack of data referring to the adequacy of the follow-up of patients and secondarily due the lack of comparability of patients. Progression - free survival was significantly better in the negative peritoneal cytology group (HR 2.07, 95% CI 1.73, 2.48 respectively), however, overall survival did not reach a significant difference among the two groups (HR 1.90, 95% CI 0.99, 3,65, p = 0.052). Our data support a negative correlation between positive peritoneal washing cytology at interval debulking surgery and the survival of ovarian cancer patients.

Identifiants

pubmed: 34678477
pii: S2468-7847(21)00193-8
doi: 10.1016/j.jogoh.2021.102256
pii:
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102256

Informations de copyright

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Auteurs

Athanasios Douligeris (A)

Gynaecological Oncology Unit, 1st Department of Obstetrics and Gynecology, Alexandra General Hospital, University of Athens, Greece. Electronic address: thanosdouligeris92@gmail.com.

Vasilios Pergialiotis (V)

Gynaecological Oncology Unit, 1st Department of Obstetrics and Gynecology, Alexandra General Hospital, University of Athens, Greece.

Zacharias Fasoulakis (Z)

Gynaecological Oncology Unit, 1st Department of Obstetrics and Gynecology, Alexandra General Hospital, University of Athens, Greece.

Alexandros Rodolakis (A)

Gynaecological Oncology Unit, 1st Department of Obstetrics and Gynecology, Alexandra General Hospital, University of Athens, Greece.

Dimitrios Haidopoulos (D)

Gynaecological Oncology Unit, 1st Department of Obstetrics and Gynecology, Alexandra General Hospital, University of Athens, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH